Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion  ReutersWhy Amgen Thinks Celgene’s Psoriasis Drug Otezla Is Worth $13.4 Billion  Bloomberg Markets and FinanceBristol-Myers Moves Closer to Buying Celgene  The Wall Street JournalBristol-Meyers Deal for Celgene Moves Ahead After Sale of Psoriasis Drug Otezla  Barron’sJim Cramer: Why It Doesn’t Matter How Much Amgen Paid for Otzela  TheStreet.comView full coverage on Google News

Loading…

Read full article